AU2017281038B2 - AR+ breast cancer treatment methods - Google Patents

AR+ breast cancer treatment methods Download PDF

Info

Publication number
AU2017281038B2
AU2017281038B2 AU2017281038A AU2017281038A AU2017281038B2 AU 2017281038 B2 AU2017281038 B2 AU 2017281038B2 AU 2017281038 A AU2017281038 A AU 2017281038A AU 2017281038 A AU2017281038 A AU 2017281038A AU 2017281038 B2 AU2017281038 B2 AU 2017281038B2
Authority
AU
Australia
Prior art keywords
inhibitor
inhibitors
use according
subject
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017281038A
Other languages
English (en)
Other versions
AU2017281038A1 (en
Inventor
Teeru BIHANI
Gary Hattersley
Chris Miller
Jamal SAEH
Ziyang YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ellipses Pharma Ltd
Original Assignee
Ellipses Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellipses Pharma Ltd filed Critical Ellipses Pharma Ltd
Publication of AU2017281038A1 publication Critical patent/AU2017281038A1/en
Assigned to RADIUS PHARMACEUTICALS, INC. reassignment RADIUS PHARMACEUTICALS, INC. Request for Assignment Assignors: RADIUS HEALTH, INC.
Assigned to ELLIPSES PHARMA LTD reassignment ELLIPSES PHARMA LTD Request for Assignment Assignors: RADIUS PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2017281038B2 publication Critical patent/AU2017281038B2/en
Priority to AU2021282467A priority Critical patent/AU2021282467B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017281038A 2016-06-22 2017-06-20 AR+ breast cancer treatment methods Active AU2017281038B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021282467A AU2021282467B2 (en) 2016-06-22 2021-12-08 AR+ breast cancer treatment methods

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662353350P 2016-06-22 2016-06-22
US62/353,350 2016-06-22
US201662377497P 2016-08-19 2016-08-19
US62/377,497 2016-08-19
US201762461546P 2017-02-21 2017-02-21
US62/461,546 2017-02-21
PCT/US2017/038390 WO2017223115A1 (en) 2016-06-22 2017-06-20 Ar+ breast cancer treatment methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021282467A Division AU2021282467B2 (en) 2016-06-22 2021-12-08 AR+ breast cancer treatment methods

Publications (2)

Publication Number Publication Date
AU2017281038A1 AU2017281038A1 (en) 2019-01-03
AU2017281038B2 true AU2017281038B2 (en) 2021-09-09

Family

ID=60675862

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017281038A Active AU2017281038B2 (en) 2016-06-22 2017-06-20 AR+ breast cancer treatment methods
AU2021282467A Active AU2021282467B2 (en) 2016-06-22 2021-12-08 AR+ breast cancer treatment methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021282467A Active AU2021282467B2 (en) 2016-06-22 2021-12-08 AR+ breast cancer treatment methods

Country Status (22)

Country Link
US (3) US20170368036A1 (cg-RX-API-DMAC7.html)
EP (2) EP3474841B1 (cg-RX-API-DMAC7.html)
JP (2) JP7221699B2 (cg-RX-API-DMAC7.html)
KR (3) KR102397890B1 (cg-RX-API-DMAC7.html)
AU (2) AU2017281038B2 (cg-RX-API-DMAC7.html)
CA (1) CA3027563C (cg-RX-API-DMAC7.html)
CY (1) CY1125213T1 (cg-RX-API-DMAC7.html)
DK (1) DK3474841T3 (cg-RX-API-DMAC7.html)
ES (1) ES2913470T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220619T1 (cg-RX-API-DMAC7.html)
IL (2) IL292659A (cg-RX-API-DMAC7.html)
LT (1) LT3474841T (cg-RX-API-DMAC7.html)
MX (2) MX389702B (cg-RX-API-DMAC7.html)
NZ (2) NZ789516A (cg-RX-API-DMAC7.html)
PL (1) PL3474841T3 (cg-RX-API-DMAC7.html)
PT (1) PT3474841T (cg-RX-API-DMAC7.html)
RS (1) RS63311B1 (cg-RX-API-DMAC7.html)
RU (2) RU2769527C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201811225RA (cg-RX-API-DMAC7.html)
SI (1) SI3474841T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200199T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017223115A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
EP3474841B1 (en) 2016-06-22 2022-03-16 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
JP2021509680A (ja) 2018-01-08 2021-04-01 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｇ１ｔ３８の優れた投与レジメン
US20190240198A1 (en) * 2018-02-05 2019-08-08 Dean G. Tang Formulations and methods for the treatment of cancers
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
AU2020248105A1 (en) * 2019-03-28 2021-11-11 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020254299A1 (en) * 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
KR20220044528A (ko) * 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
BR112022008683A2 (pt) 2019-11-05 2022-07-19 Abbvie Inc Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax
JP2023522040A (ja) 2020-04-17 2023-05-26 エッサ ファーマ，インコーポレイテッド Ｎ末端ドメインアンドロゲン受容体阻害剤の固体形態およびその使用
WO2022046594A1 (en) * 2020-08-23 2022-03-03 Texas Biomedical Research Institute Treatment of infectious diseases using bcl-2 family protein inhibitors
CN112321526B (zh) * 2020-09-30 2023-09-22 西北师范大学 一种通过氧化还原-脱羧偶联反应合成杂芳甲胺类化合物的方法
KR20230163362A (ko) * 2021-01-15 2023-11-30 유니버시티 오브 테네시 리서치 파운데이션 유방암 치료용 약제학적 조성물 및 이의 사용 방법
WO2022174121A1 (en) * 2021-02-11 2022-08-18 Veru, Inc. Methods of prescreening and treating breast cancers with selective androgen receptor modulators
US20240082166A1 (en) * 2021-03-26 2024-03-14 Impact Therapeutics (Shanghai), Inc Oral capsule of parp inhibitor and preparation method thereof
WO2023064782A2 (en) * 2021-10-12 2023-04-20 Baylor College Of Medicine Transcriptional reprogramming differentiates active from inactive esr1 fusions in endocrine therapy-refractory metastatic breast cancer
WO2025122500A1 (en) * 2023-12-04 2025-06-12 Foundation Medicine, Inc. Esr1 gene fusions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110224267A1 (en) * 2008-02-22 2011-09-15 Radius Health,Inc. Selective androgen receptor modulators
US20120004270A1 (en) * 2010-07-02 2012-01-05 Radius Health, Inc. Selective Androgen Receptor Modulators
US20140350102A1 (en) * 2012-07-13 2014-11-27 Gtx, Inc. Method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US20160128968A1 (en) * 2012-07-13 2016-05-12 Gtx, Inc. Method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1547758A (en) 1975-07-29 1979-06-27 Shell Int Research Herbicidal composition
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
UA51652C2 (uk) 1995-06-08 2002-12-16 Новартіс Аг Спосіб гідрування імінів
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
WO1997049709A1 (en) 1996-06-27 1997-12-31 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
FR2770842B1 (fr) 1997-11-13 1999-12-17 Oreal Nouveaux composes derives de n-aryl 2-hydroxy alkylamides
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6159959A (en) 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
WO2001036039A2 (en) 1999-11-17 2001-05-25 Novartis Ag Iontophoretic transdermal delivery of peptides
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
KR20020075388A (ko) 1999-12-30 2002-10-04 시그널 파머슈티컬스 인크 에스트로겐 수용체의 조절 화합물 및 조절 방법
AU2001288213B2 (en) 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
ATE356636T1 (de) 2000-08-03 2007-04-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
ATE344233T1 (de) 2000-08-24 2006-11-15 Univ Tennessee Res Corp Selektive modulatoren des andro genrezeptors und methoden zu deren verwendung
AU2006201538B2 (en) 2000-08-24 2008-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
EP2085109A3 (en) 2000-10-26 2009-09-02 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US6670386B2 (en) 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
JP2005502654A (ja) 2001-08-13 2005-01-27 メルク　エンド　カムパニー　インコーポレーテッド 選択的エストロゲン受容体調節剤
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
WO2003068217A1 (en) 2002-02-15 2003-08-21 Endorecherche, Inc. Biphenil derivatives and their use as antiandrogenic agents
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
CA2484038C (en) 2002-04-24 2011-10-18 Merck & Co., Inc. Estrogen receptor modulators
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
CA2496618A1 (en) 2002-05-23 2003-12-04 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
JP4449746B2 (ja) 2002-07-12 2010-04-14 アステラス製薬株式会社 Ｎ−フェニル−（２ｒ，５ｓ）ジメチルピペラジン誘導体
EP1553074B1 (en) 2002-08-12 2014-06-18 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
JP2006513159A (ja) 2002-11-01 2006-04-20 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
AU2003292625B2 (en) 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
WO2004080377A2 (en) 2003-03-11 2004-09-23 Neurosearch A/S Kcnq channel modulating compounds and their pharmaceutical use
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
JP2007500245A (ja) 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
WO2004110978A2 (en) 2003-06-10 2004-12-23 Smithkline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
KR20060038407A (ko) 2003-06-30 2006-05-03 알자 코포레이션 비휘발성 반대이온을 포함하는 코팅된 미세돌출부용 제제
EP1643978A1 (en) 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
US7446110B2 (en) 2003-09-10 2008-11-04 Merck & Co., Inc. 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
BRPI0415629A (pt) 2003-10-31 2006-12-12 Alza Corp aplicador auto-atuador para conjunto de microprojeções
WO2005051456A2 (en) 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
BRPI0416208A (pt) 2003-11-20 2006-12-26 Warner Lambert Co moduladores de receptores de androgênio
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
CA2551737C (en) 2004-01-07 2009-11-10 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
CA2551956C (en) 2004-01-22 2013-05-07 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
JP4805909B2 (ja) 2004-03-03 2011-11-02 スミスクライン ビーチャム コーポレーション 選択的アンドロゲン受容体モジュレーターとしてのアニリン誘導体
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP2007223901A (ja) 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
JP2007532550A (ja) 2004-04-08 2007-11-15 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレーターとしての１７−β−アセトアミド−４−アザステロイド
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
AU2005243239C1 (en) 2004-05-03 2013-10-24 Janssen Pharmaceutica N.V. Indole, benzofuran and benzothiophene derivatives as selective androgen receptor modulators (SARMS)
US20080045504A1 (en) 2004-05-11 2008-02-21 Pfizer Products Inc. Benzonitrile Derivatives to Treat Musculoskeletal Frailty
US7556821B2 (en) 2004-05-13 2009-07-07 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
CA2566942A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
EA200602288A1 (ru) 2004-05-29 2007-10-26 7ТиЭм ФАРМА А/С Замещённые тиазолуксусные кислоты в качестве лигандов crth2
PL1753417T3 (pl) 2004-06-07 2012-09-28 Univ Tennessee Res Found Selektywny modulator receptora androgenowego i jego zastosowania medyczne
CN101056862B (zh) 2004-09-10 2013-03-13 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的咪唑烷-2-酮衍生物
ATE514700T1 (de) 2004-09-20 2011-07-15 Janssen Pharmaceutica Nv Neues tetrazyklisches heteroatom mit als sexualsteroidhormon-rezeptormodulatoren geeigneten derivaten
JP4953456B2 (ja) 2004-09-30 2012-06-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）として有用な新規なベンゾイミダゾール誘導体
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2006044707A1 (en) 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
CA2585276A1 (en) 2004-10-29 2006-06-08 Merck & Co., Inc. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
CN101103003A (zh) 2004-11-16 2008-01-09 詹森药业有限公司 用作选择性雄激素受体调节剂(sarms)的新的杂环衍生物
WO2006054299A2 (en) 2004-11-18 2006-05-26 Transpharma Medical Ltd. Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
JP5203712B2 (ja) 2005-01-10 2013-06-05 アカディア ファーマシューティカルズ インコーポレイテッド 選択的アンドロゲン受容体モジュレータとしてのアミノフェニル誘導体
US20080194536A1 (en) 2005-04-15 2008-08-14 Marlys Hammond Cyanoarylamines
ATE412647T1 (de) 2005-05-13 2008-11-15 Lilly Co Eli Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
US20090170907A1 (en) 2005-06-06 2009-07-02 Smithkline Beecham Corporation Chemical Compounds
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
WO2007002181A2 (en) 2005-06-24 2007-01-04 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
AR057656A1 (es) 2005-07-01 2007-12-12 Ligand Pharm Inc Compuestos moduladores de receptores de androgeno y metodods relacionados
WO2007015567A1 (ja) 2005-08-01 2007-02-08 Takeda Pharmaceutical Company Limited 環状アミン化合物
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
US7776859B2 (en) 2005-10-14 2010-08-17 Bristol-Myers Squibb Company Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function
EP1945224B1 (en) * 2005-10-19 2012-05-02 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
WO2007061964A1 (en) 2005-11-18 2007-05-31 3M Innovative Properties Company Methods for coating microneedles
TW200730505A (en) 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
WO2007084247A2 (en) 2005-12-28 2007-07-26 Alza Corporation Stable therapeutic formulations
RS52756B (sr) 2006-01-24 2013-08-30 Janssen Pharmaceutica N.V. 2-supstituisani benzimidazoli kao selektivni modulatori androgenih receptora
JP5373405B2 (ja) 2006-03-03 2013-12-18 オリオン コーポレーション 選択的アンドロゲン受容体モジュレーター
CA2680690A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
DK2038252T3 (en) 2006-07-12 2016-12-19 Univ Tennessee Res Found SUBSTITUTED AND ACYLANILIDER methods of use thereof
JP2009543871A (ja) 2006-07-19 2009-12-10 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 選択的アンドロゲン受容体調節薬、その類似体及び誘導体とそれらの使用
EP3056483A1 (en) 2006-08-24 2016-08-17 University of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
ES2452343T3 (es) 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
AU2007322334B2 (en) 2006-10-03 2011-12-22 Ipsen Pharma S.A.S. Method of drug delivery for bone anabolic protein
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US7696227B2 (en) 2007-04-13 2010-04-13 Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
AU2008241470B2 (en) 2007-04-16 2013-11-07 Corium Pharma Solutions, Inc. Solvent-cast microneedle arrays containing active
GB0712099D0 (en) 2007-06-22 2007-08-01 Wivenhoe Technology Ltd Transmission Of Audio Information
AR067823A1 (es) 2007-08-07 2009-10-21 Takeda Pharmaceutical Compuestos de amina ciclica
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
US20110105554A1 (en) 2007-11-21 2011-05-05 Kinaris Biomedicals Gmbh Means for treating myosin-related diseases
BRPI0821676A2 (pt) 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
CA2709677C (en) 2007-12-21 2017-03-14 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
US20110124617A1 (en) 2008-05-09 2011-05-26 Lyttle C Richard Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
HRP20120917T1 (hr) 2008-05-16 2012-12-31 Eli Lilly & Company TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
KR101634836B1 (ko) 2008-12-26 2016-06-29 히사미쓰 세이야꾸 가부시키가이샤 마이크로 니들 디바이스
US8629157B2 (en) 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
DK2433940T3 (en) 2009-04-28 2015-01-12 Chugai Pharmaceutical Co Ltd Spiroimidazolonderivat
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
JP5606778B2 (ja) 2010-04-22 2014-10-15 大倉工業株式会社 手術用資材
WO2011140274A2 (en) 2010-05-04 2011-11-10 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
EP2575845B1 (en) 2010-05-28 2017-02-15 3M Innovative Properties Company Aqueous formulations for coating microneedle arrays
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
SG194570A1 (en) 2011-04-22 2013-12-30 Radius Health Inc Method of drug delivery for pth, pthrp and related peptides
US9675675B2 (en) 2011-11-30 2017-06-13 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
US10258596B2 (en) * 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) * 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9408847B2 (en) * 2012-11-28 2016-08-09 Novartis Ag Combination therapy
KR20140080905A (ko) 2012-12-20 2014-07-01 주식회사 비즈모델라인 무매체 결제 서비스 제공 방법
US20160128988A1 (en) 2013-06-11 2016-05-12 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
BR112015031729A2 (pt) * 2013-06-19 2017-07-25 Univ Miami sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama
EP3474841B1 (en) 2016-06-22 2022-03-16 Ellipses Pharma Ltd Ar+ breast cancer treatment methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110224267A1 (en) * 2008-02-22 2011-09-15 Radius Health,Inc. Selective androgen receptor modulators
US20120004270A1 (en) * 2010-07-02 2012-01-05 Radius Health, Inc. Selective Androgen Receptor Modulators
US20140350102A1 (en) * 2012-07-13 2014-11-27 Gtx, Inc. Method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US20160128968A1 (en) * 2012-07-13 2016-05-12 Gtx, Inc. Method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRIS P. MILLER ET AL, "Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140", ACS MED. CHEM. LETT. 2(2), pg 124-129, (2010-12-02), doi:10.1021/ml1002508 *
COSS CHRISTOPHER C ET AL, "Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer", STEROIDS, (2014-06-16), vol. 90, doi:10.1016/J.STEROIDS.2014.06.010, ISSN 0039-128X, pages 94 - 100 *

Also Published As

Publication number Publication date
EP3474841A1 (en) 2019-05-01
HRP20220619T1 (hr) 2023-02-03
MX389702B (es) 2025-03-20
RU2022108295A (ru) 2022-04-06
AU2021282467B2 (en) 2024-02-08
US11771682B2 (en) 2023-10-03
SI3474841T1 (sl) 2023-02-28
AU2017281038A1 (en) 2019-01-03
BR112018076001A2 (pt) 2019-03-26
DK3474841T3 (da) 2022-05-09
AU2021282467A1 (en) 2022-01-06
RU2018144427A3 (cg-RX-API-DMAC7.html) 2020-10-16
SG11201811225RA (en) 2019-01-30
JP7628560B2 (ja) 2025-02-10
SMT202200199T1 (it) 2022-07-21
US12329746B2 (en) 2025-06-17
CY1125213T1 (el) 2025-03-28
KR20220035276A (ko) 2022-03-21
CA3027563A1 (en) 2017-12-28
CA3027563C (en) 2024-07-02
RU2018144427A (ru) 2020-07-22
US20170368036A1 (en) 2017-12-28
PL3474841T3 (pl) 2022-07-11
US20200171008A1 (en) 2020-06-04
MX2022001075A (es) 2022-02-14
KR102785824B1 (ko) 2025-03-21
NZ789516A (en) 2025-07-25
IL263678B (en) 2022-06-01
ES2913470T3 (es) 2022-06-02
KR20190021355A (ko) 2019-03-05
EP3474841A4 (en) 2020-07-22
NZ749192A (en) 2022-07-29
US20240207234A1 (en) 2024-06-27
EP4066827A1 (en) 2022-10-05
PT3474841T (pt) 2022-06-20
IL292659A (en) 2022-07-01
KR20240090491A (ko) 2024-06-21
RS63311B1 (sr) 2022-07-29
JP2023055861A (ja) 2023-04-18
WO2017223115A1 (en) 2017-12-28
MX2018015724A (es) 2019-04-29
JP2019518765A (ja) 2019-07-04
JP7221699B2 (ja) 2023-02-14
LT3474841T (lt) 2022-06-10
IL263678A (en) 2019-01-31
KR102397890B1 (ko) 2022-05-12
EP3474841B1 (en) 2022-03-16
RU2769527C2 (ru) 2022-04-01

Similar Documents

Publication Publication Date Title
AU2021282467B2 (en) AR+ breast cancer treatment methods
JP7745708B2 (ja) 癌を治療するための方法
HK40080890A (en) Ar+ breast cancer treatment methods
BR112018076001B1 (pt) Uso de rad140 (composto iii) para tratamento de câncer de mama ar+/ er+"

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RADIUS PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): RADIUS HEALTH, INC.

PC1 Assignment before grant (sect. 113)

Owner name: ELLIPSES PHARMA LTD

Free format text: FORMER APPLICANT(S): RADIUS PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)